BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 922 filers reported holding BAXTER INTL INC in Q1 2024. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $17,946,147 | -28.0% | 575,001 | -8.6% | 0.03% | -27.3% |
Q1 2024 | $24,909,228 | +17.5% | 629,433 | +3.9% | 0.04% | +7.3% |
Q4 2023 | $21,197,257 | -20.8% | 605,679 | -14.6% | 0.04% | -25.5% |
Q3 2023 | $26,757,245 | -19.0% | 708,989 | -10.3% | 0.06% | -17.9% |
Q2 2023 | $33,022,147 | +5.2% | 790,763 | -6.0% | 0.07% | 0.0% |
Q1 2023 | $31,400,149 | +68050.1% | 841,092 | -7.0% | 0.07% | -23.9% |
Q4 2022 | $46,075 | -99.8% | 903,961 | +84.0% | 0.09% | +25.7% |
Q3 2022 | $27,009,000 | -42.9% | 491,266 | -36.2% | 0.07% | -36.9% |
Q2 2022 | $47,306,000 | -21.0% | 769,981 | -10.4% | 0.11% | -1.8% |
Q1 2022 | $59,889,000 | -18.2% | 859,370 | -11.4% | 0.11% | -8.9% |
Q4 2021 | $73,202,000 | +5.4% | 969,770 | -3.1% | 0.12% | +0.8% |
Q3 2021 | $69,425,000 | +2.0% | 1,000,370 | -0.2% | 0.12% | +6.0% |
Q2 2021 | $68,055,000 | -4.3% | 1,002,570 | +1.2% | 0.12% | -4.1% |
Q1 2021 | $71,110,000 | -10.1% | 990,939 | -17.8% | 0.12% | -6.2% |
Q4 2020 | $79,095,000 | +61.0% | 1,206,087 | +68.3% | 0.13% | +51.8% |
Q3 2020 | $49,137,000 | -10.0% | 716,495 | +0.6% | 0.08% | -14.1% |
Q2 2020 | $54,573,000 | -34.4% | 711,895 | -30.6% | 0.10% | +20.7% |
Q1 2020 | $83,236,000 | +789.1% | 1,025,210 | +715.8% | 0.08% | +446.7% |
Q4 2019 | $9,362,000 | -25.7% | 125,671 | -20.0% | 0.02% | -28.6% |
Q3 2019 | $12,608,000 | +3.4% | 157,137 | -7.3% | 0.02% | 0.0% |
Q2 2019 | $12,197,000 | +11.6% | 169,595 | +12.3% | 0.02% | +5.0% |
Q1 2019 | $10,934,000 | -27.1% | 150,995 | -42.0% | 0.02% | +33.3% |
Q4 2018 | $14,992,000 | -83.5% | 260,390 | -81.0% | 0.02% | -90.6% |
Q3 2018 | $91,119,000 | -27.8% | 1,372,867 | -31.2% | 0.16% | -31.0% |
Q2 2018 | $126,245,000 | -48.8% | 1,996,167 | -57.2% | 0.23% | -51.4% |
Q1 2018 | $246,573,000 | -52.8% | 4,662,477 | -52.0% | 0.48% | -0.2% |
Q4 2017 | $522,458,000 | +65.7% | 9,705,554 | +93.1% | 0.48% | -7.9% |
Q3 2017 | $315,368,000 | +19.1% | 5,025,777 | +14.9% | 0.52% | +7.9% |
Q2 2017 | $264,776,000 | +38.7% | 4,373,577 | +18.8% | 0.48% | +37.4% |
Q1 2017 | $190,935,000 | +18.9% | 3,681,737 | -3.7% | 0.35% | +15.9% |
Q4 2016 | $160,643,000 | -8.4% | 3,821,338 | +3.7% | 0.30% | -1.9% |
Q3 2016 | $175,341,000 | +32.3% | 3,683,638 | +25.7% | 0.31% | +23.7% |
Q2 2016 | $132,501,000 | +39.2% | 2,930,138 | +26.4% | 0.25% | +25.8% |
Q1 2016 | $95,212,000 | -99.9% | 2,317,726 | +34.9% | 0.20% | +31.1% |
Q4 2015 | $65,531,667,000 | +133580.8% | 1,717,737 | +15.1% | 0.15% | +34.8% |
Q3 2015 | $49,021,000 | -40.9% | 1,492,263 | +25.8% | 0.11% | -32.5% |
Q2 2015 | $82,921,000 | +130.8% | 1,185,778 | +126.0% | 0.17% | +124.3% |
Q1 2015 | $35,935,000 | -25.4% | 524,595 | -20.2% | 0.07% | -19.6% |
Q4 2014 | $48,201,000 | +2.1% | 657,676 | -0.0% | 0.09% | -3.2% |
Q3 2014 | $47,217,000 | +1.1% | 657,894 | +1.8% | 0.10% | -5.0% |
Q2 2014 | $46,722,000 | +11.2% | 646,223 | +13.1% | 0.10% | -9.1% |
Q1 2014 | $42,029,000 | -43.3% | 571,195 | -46.4% | 0.11% | +0.9% |
Q4 2013 | $74,156,000 | +102.6% | 1,066,228 | +91.4% | 0.11% | -6.0% |
Q3 2013 | $36,595,000 | -22.8% | 557,087 | -18.6% | 0.12% | -21.6% |
Q2 2013 | $47,392,000 | – | 684,160 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |